These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31195080)

  • 1. Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice.
    Dimitriadis GK; Nasiri-Ansari N; Agrogiannis G; Kostakis ID; Randeva MS; Nikiteas N; Patel VH; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Mol Cell Endocrinol; 2019 Aug; 494():110487. PubMed ID: 31195080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice.
    Nasiri-Ansari Ν; Dimitriadis GK; Agrogiannis G; Perrea D; Kostakis ID; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Cardiovasc Diabetol; 2018 Jul; 17(1):106. PubMed ID: 30049285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity.
    Liu Y; Xu J; Wu M; Xu B; Kang L
    Lipids Health Dis; 2021 Jan; 20(1):5. PubMed ID: 33436015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice.
    Pennig J; Scherrer P; Gissler MC; Anto-Michel N; Hoppe N; Füner L; Härdtner C; Stachon P; Wolf D; Hilgendorf I; Mullick A; Bode C; Zirlik A; Goldberg IJ; Willecke F
    Sci Rep; 2019 Nov; 9(1):17937. PubMed ID: 31784656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice.
    Ganbaatar B; Fukuda D; Shinohara M; Yagi S; Kusunose K; Yamada H; Soeki T; Hirata KI; Sata M
    Eur J Pharmacol; 2020 May; 875():173040. PubMed ID: 32114052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE
    Nasiri-Ansari N; Nikolopoulou C; Papoutsi K; Kyrou I; Mantzoros CS; Kyriakopoulos G; Chatzigeorgiou A; Kalotychou V; Randeva MS; Chatha K; Kontzoglou K; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE
    Han JH; Oh TJ; Lee G; Maeng HJ; Lee DH; Kim KM; Choi SH; Jang HC; Lee HS; Park KS; Kim YB; Lim S
    Diabetologia; 2017 Feb; 60(2):364-376. PubMed ID: 27866224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation inhibition and gut microbiota regulation by TSG to combat atherosclerosis in ApoE
    Li F; Zhang T; He Y; Gu W; Yang X; Zhao R; Yu J
    J Ethnopharmacol; 2020 Jan; 247():112232. PubMed ID: 31606534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance.
    Taberner-Cortés A; Vinué Á; Herrero-Cervera A; Aguilar-Ballester M; Real JT; Burks DJ; Martínez-Hervás S; González-Navarro H
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
    Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role.
    Fu J; Xu H; Wu F; Tu Q; Dong X; Xie H; Cao Z
    Int J Cardiol; 2022 Nov; 367():56-62. PubMed ID: 35931206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crocus sativus L. aqueous extract reduces atherogenesis, increases atherosclerotic plaque stability and improves glucose control in diabetic atherosclerotic animals.
    Christodoulou E; Kadoglou NPE; Stasinopoulou M; Konstandi OA; Kenoutis C; Kakazanis ZI; Rizakou A; Kostomitsopoulos N; Valsami G
    Atherosclerosis; 2018 Jan; 268():207-214. PubMed ID: 29128090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice].
    Luo RN; Tao LJ; Zhou J; Wang R; Lu MM; Fu X
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):743-8. PubMed ID: 22169423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipingshu capsule improves atherosclerosis associated with lipid regulation and inflammation inhibition in apolipoprotein E-deficient mice.
    Xu J; Ma C; Chen M; Rong S; Gao H; Xia Z; Huang F
    Lipids Health Dis; 2018 Jul; 17(1):182. PubMed ID: 30064511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suxiaojiuxin pill enhances atherosclerotic plaque stability by modulating the MMPs/TIMPs balance in ApoE-deficient mice.
    Zhang J; Zhuang P; Lu Z; Zhang M; Zhang T; Zhang Y; Wang J; Liu D; Tong Y
    J Cardiovasc Pharmacol; 2014 Aug; 64(2):120-6. PubMed ID: 24621651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
    Cheng ST; Chen L; Li SY; Mayoux E; Leung PS
    PLoS One; 2016; 11(1):e0147391. PubMed ID: 26807719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation.
    Benetti E; Mastrocola R; Vitarelli G; Cutrin JC; Nigro D; Chiazza F; Mayoux E; Collino M; Fantozzi R
    J Pharmacol Exp Ther; 2016 Oct; 359(1):45-53. PubMed ID: 27440421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
    Oelze M; Kröller-Schön S; Welschof P; Jansen T; Hausding M; Mikhed Y; Stamm P; Mader M; Zinßius E; Agdauletova S; Gottschlich A; Steven S; Schulz E; Bottari SP; Mayoux E; Münzel T; Daiber A
    PLoS One; 2014; 9(11):e112394. PubMed ID: 25402275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carvedilol reduces the severity of atherosclerosis in apolipoprotein E-deficient mice via reducing superoxide production.
    Shimada K; Hirano E; Kimura T; Fujita M; Kishimoto C
    Exp Biol Med (Maywood); 2012 Sep; 237(9):1039-44. PubMed ID: 22946091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.